法司努单抗
化合物
法司努单抗（INN：Fasinumab）是一种人单克隆抗体，设计用于治疗急性坐骨神经痛。[1][2]该药物由梯瓦制药工业有限公司和再生元制药公司合作开发。目前正处于III期试验（NCT03245008、NCT02683239和NCT03161093）。[3]
| 单克隆抗体 | |
|---|---|
| 种类 | ? |
| 目标 | HNGF |
| 临床资料 | |
| ATC码 |
|
| 识别信息 | |
| CAS号 | 1190239-42-9 |
| ChemSpider |
|
| UNII | |
| KEGG | |
| 化学信息 | |
| 化学式 | C6406H9896N1700O2026S46 |
| 摩尔质量 | 144,618.27 g·mol−1 |
参考资料
编辑- ^ Fasinumab (PDF). Statement On A Nonproprietary Name Adopted By The USAN Council. American Medical Association. [2023-12-06]. （原始内容存档 (PDF)于2020-04-14）.
- ^ Tiseo PJ, Ren H, Mellis S. Fasinumab (REGN475), an antinerve growth factor monoclonal antibody, for the treatment of acute sciatic pain: results of a proof-of-concept study. Journal of Pain Research. 2014, 7: 523–530. PMC 4155988
. PMID 25210473. doi:10.2147/JPR.S65974 .
- ^ Oo WM, Hunter DJ. Nerve Growth Factor (NGF) Inhibitors and Related Agents for Chronic Musculoskeletal Pain: A Comprehensive Review. BioDrugs. November 2021, 35 (6): 611–641. PMID 34807432. S2CID 244509341. doi:10.1007/s40259-021-00504-8.
